Company: RNAC
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001453687-25-000120
Chunk: 129

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 129
---
 nine months ended September 30, 2024, respectively.

14. Related-Party Transactions

2024 Securities Purchase AgreementOn July 2, 2024, the Company entered into the 2024 Securities Purchase Agreement with the Purchasers. The Purchasers included (i) Dr. Timothy A. Springer, a member of the Company’s Board of Directors; (ii) TAS Partners LLC, an affiliate of Dr. Springer, and (iii) Dr. Chafen Lu, Dr. Springer’s wife. See Note 11, “Convertible Preferred Stock” to the consolidated 

26

financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 for further discussion of the 2024 Private Placement. The below issuances and sales to related parties of the Company were made during the nine months ended September 30, 2024.NameShares of Series B Preferred Stock purchasedTotal aggregate purchase price(in thousands)Timothy A. Springer, Ph.D.1,636,832 $32,737 TAS Partners LLC, affiliate of Timothy A. Springer, Ph.D.721,361 $14,427 Chafen Lu, Ph.D., wife of Timothy A. Springer, Ph.D.1,307 $26 2023 Securities Purchase AgreementOn November 13, 2023, the Company entered into the 2023 Securities Purchase Agreement with (i) Dr. Timothy A. Springer, a member of the Company’s Board of Directors, (ii) TAS Partners LLC, an affiliate of Dr. Springer, and (iii) Seven One Eight Three Four Irrevocable Trust, a trust associated with Dr. Murat Kalayoglu, a member of the Company’s Board of Directors, or the Investors, in which the Company agreed to issue and sell an aggregate of 149,330.115 shares of Series A Preferred Stock for an aggregate purchase price of $60.25 million. See Note 11, “Convertible Preferred Stock” to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 for further discussion of the 2023 Private Placement. The 2023 Private Placement included a delayed settlement mechanism, and as a result, the below issuances and sales to related parties of the Company were made during the nine months ended September 30, 2024.NameShares of Series A Preferred Stock purchasedTotal aggregate purchase price(in thousands)Tim